Skip to main content
Professional Technical IVT

cytotoxic T-lymphocyte-associated protein 4

Pronunciation: SY-toe-TOX-ik TEE lim-fo-site as-SO-see-ay-ted PRO-teen

Also written as: CTLA-4 — cytotoxic T-lymphocyte-associated protein 4

A protein receptor that acts as an immune checkpoint, downregulating immune responses.

Full Definition

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a protein receptor found on T cells that functions as an immune checkpoint by inhibiting T-cell activation and proliferation. In cancer treatment, CTLA-4 inhibitors are used as immunotherapy drugs to enhance the immune system's ability to attack cancer cells. The protein plays a crucial role in maintaining immune homeostasis by preventing excessive immune responses. CTLA-4 blockade has shown significant clinical efficacy in treating various cancers, particularly melanoma.

Usage

Usage note: Always spell out on first use, then use CTLA-4. Hyphenate the full form.

In Context

  • "The patient was enrolled in a clinical trial testing a CTLA-4 inhibitor for advanced melanoma." — Clinical trial protocol
  • "Expression levels of cytotoxic T-lymphocyte-associated protein 4 were analyzed using flow cytometry." — Research manuscript

Also known as

CTLA-4

Don't confuse with

PD-1 PD-L1

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON